A further phase 1b study of ponsegromab was started in patients with advanced cancer, anorexia and elevated circulating levels of GDF‐15 ≥1.5 ng/mL, randomized to either ponsegromab of 200 mg SC every 3 weeks or placebo during a 6‐week double‐blind period followed by an optional 18‐week open‐label treatment period23; however, this study was terminated early to focus on the current phase 2 study after enrolment of only 18 participants, less than half of the planned sample size. This evidence concerns the gene GDF15 and cancer.